Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients.
Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print].
Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print].
Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors.
Jouni H et al. Am J Hematol. 2016 Nov 17. doi: 10.1002/ajh.24608. [Epub ahead of print].
Epibulbar Plasmacytoma Masquerading as Subconjunctival Hemorrhage in a Patient With Multiple Myeloma.
Bradley A et al. Cornea. 2016 Nov 16. [Epub ahead of print].
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Tochigi T et al. Int J Hematol. 2016 Nov 21. [Epub ahead of print].
Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.
Zhu W et al. Medicine (Baltimore). 2016 Nov;95(46):e5202.
Corneal Densitometry for Quantification of Corneal Deposits in Monoclonal Gammopathies.
Enders P et al. Cornea. 2016 Nov 10. [Epub ahead of print].
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Reneau JC et al. Am J Hematol. 2016 Nov 4. doi: 10.1002/ajh.24599. [Epub ahead of print].
Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
Hwang S et al.Int J Dermatol. 2016 Nov 2. doi: 10.1111/ijd.13431. [Epub ahead of print].
Treatment of Multiple Myeloma in a Heart Transplant Recipient: Focus on the Immunomodulatory Effects of Lenalidomide.
Xie L et al. Prog Transplant. 2016 Nov 24. pii: 1526924816679842. [Epub ahead of print].